Company:  XBIOTECH INC. (XBIT)
Form Type:  SC TO-I
Filing Date:  1/14/2020 
CIK:  0001626878 
Address:  8201 E. RIVERSIDE DRIVE
BUILDING 4, SUITE 100
 
City, State, Zip:  AUSTIN, Texas 78744 
Telephone:  512-386-2930 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$24.30  
Change: 
-0.595 (-2.39%)  
Trade Time: 
Jan 17  
Market Cap: 
$1.03B
Trade XBIT now with

© 2020  
Description of Business
XBiotech Inc. ("XBiotech" or the "Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human(TM) monoclonal antibodies for treating a variety of diseases. True Human(TM) monoclonal antibodies are those which occur naturally in human beings--as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human(TM) pipeline and manufacturing system. The majority of our efforts to date have been concentrated on developing our lead product candidate, bermekimab (also known as MABp1, Xilonix(TM), CA-18C3, CV-18C3, RA-18C3, and T2-18C3), a therapeutic antibody which specifically neutralizes interleukin-1 alpha (IL-1a).
Register and access this filing in:     
  FORM SC TO-I
  EXHIBIT 99.(A)(1)(I)
  EXHIBIT 99.(A)(1)(II)
  EXHIBIT 99.(A)(1)(III)
  EXHIBIT 99.(A)(1)(IV)
  EXHIBIT 99.(A)(1)(V)
  EXHIBIT 99.(A)(5)(I)
  EXHIBIT 99.(A)(5)(II)